Study design and patients
Tumors, death, toxicity, Cancer
DISEASE PROGRESSION, BEST, STAGE II NSCLC, TUMORS, ONCOLOGY, CANCER
Consecutive patients with stage III NSCLC treated at Westmead and Blacktown Hospitals in Sydney, Australia between January 2015 and July 2022 were included. All patients were discussed at the lung multidisciplinary team meeting and treatment decisions were made by consensus of the treating physicians.Retrospective data were collected for patients who received definitive concurrent chemotherapy, defined as patients who received at least two cycles of combination platinum‐based chemotherapy with radiotherapy. We collected data on demographics, Eastern Cooperative Oncology Group (ECOG) performance status, tumor‐specific features (histologic subtype, stage as per the 8th edition of the American Joint Committee on Cancer Staging Manual), oncogenic alterations (Best response to treatment was evaluated as per the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. PFS was defined as the time from completion of radiotherapy to disease progression as per RECIST criteria or death. OS was defined as the time from completion of radiotherapy to death of any cause up to December 1, 2022.Patients were defined as eligible for the PACIFIC trial if they fulfilled the inclusion criteria as specified in the clinical trial protocol (Table We collected data on reasons for trial ineligibility. For all patients who received durvalumab, we collected data on early cessation of therapy, hospitalization or corticosteroid use for treatment‐related toxicity.